The Valley Desk

NCT03787602 · Interventional trial

Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma

Overall registry status Unknown

Phase 1 · Phase 2

Conditions Merkel Cell Carcinoma

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov